YJLK Biotech Secures $60 Million Series B Financing to Advance Clinical Development of Chronic Hepatitis B Functional Cure Therapy

As a leading biotechnology company dedicated to developing the next generation of epigenetic regulation technologies for treating chronic diseases, Epigenic Therapeutics, Inc. consistently stays at the forefront of the industry.EpigenicEPIREG™ Technology Platform, with proprietary intellectual property rights, leverages precise DNA methylation and histone modification toEfficient, long-lasting, and specific silencing of target genes, compared with the traditional gene editing tools that cut DNA, provides a safer and revolutionary innovative treatment solution for patients with chronic diseases, effectively avoiding the safety concerns that may be brought by traditional gene editing.

Notably, Epigenic has independently developedIn Vivo LNP Delivery Platform—EpiTax™, which can integrate with the EPIREG™ toolPrecise delivery to the liver and multiple extrahepatic target organs, further expanding the application scope of the EPIREG™ tool in disease treatment and bringing new possibilities to the treatment of more disease fields, makingEpigenicThe technical matrix is more complete and competitive.

In addition, the AIAID™ platform established by Epigenic empowers epigenetic regulation drug molecule design, target selection, and precise control. The platform is powered by a proprietary foundational large model for epigenetics, providing accurate underlying data and algorithmic support; through a multi-agent collaborative virtual laboratory, it autonomously achieves key tasks such as target discovery, target research, accessibility prediction, sgRNA design and evaluation, virtual epigenetic regulation, and multi-omics analysis; and leverages AI-driven de novo protein design and AI-directed evolution technology to accelerate the discovery, iteration, and performance optimization process of EPIREG™.